New preclinical data involving pregabalin are consistent with peer-reviewed data involving gabapentin previously published in The Journal of Pain SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 30, 2019 /   VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need,

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 2, 2019  /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need,

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2019 /   VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that 

PH94B has potential to be the First FDA-Approved PRN Treatment for Social Anxiety Disorder New Findings Presented at the 2019 Anxiety and Depression Association of America Annual Conference SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need,

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 14, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that 

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2019 /   VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced that the

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need,

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced the